-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 30, Ganli Pharmaceutical announced that its weekly ultra-long-acting insulin weekly preparation GZR4 clinical trial application has been accepted by NMPA (acceptance number: CXSL2101457, the official website has not yet been published)
Prior to this, on October 25, the glucagon-like peptide 1 (GLP-1) receptor agonist GZR18, which was injected once a week by Ganli Pharmaceutical, had just been approved for clinical use for type II diabetes, obesity and overweight
According to the latest data released by the International Diabetes Federation (IDF) Global Diabetes Overview 9th Edition (2019), there are currently 463 million adults (20-79 years old) living with diabetes worldwide
Among the insulin drugs currently on the market, insulin analogues occupy a major share of the insulin market due to their relatively good safety and lower immunogenicity
Insulin centralized procurement group 5 winning bids
From: Shanghai Sunshine Purchasing Network, compiled by Insight
However, the half-lives of long-acting basal insulin analogues currently on the market are about 10~26 hours, and the duration of action is only about one day
Up to now, no weekly insulin preparation products have been approved for the market worldwide.
Icodec project details
From Insight database (http://db.
As of September 30, 2021, Ganli Pharmaceutical has invested a total of RMB 30.
